How to switch from combined oral contraceptive (COC) to depot medroxyprogesterone acetate (DMPA) injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Switching from Combined Oral Contraceptive to Depot Medroxyprogesterone Acetate

You can start DMPA immediately without waiting for a menstrual period—simply begin the injection at any time during the pill pack, finish the current pack of COCs, and use backup contraception (condoms or abstinence) for 7 days after the DMPA injection. 1

Timing of the Switch

  • Start DMPA at any point during your current COC pack—there is no need to wait for withdrawal bleeding or complete the pack before initiating the depot shot. 1

  • Continue taking the COC until the pack is finished to maintain contraceptive coverage during the transition, as this prevents any gap in protection. 2

  • Administer the first DMPA injection (150 mg intramuscularly or 104 mg subcutaneously) while still on the COC, ensuring overlap between methods rather than creating a gap. 3, 4

Backup Contraception Requirements

  • Use backup contraception (condoms or abstinence) for 7 days after the DMPA injection, regardless of when during the COC pack you receive the shot. 1

  • This 7-day window is necessary because while DMPA begins working immediately to suppress ovulation, the standard recommendation ensures full contraceptive efficacy is established. 1

Formulation Options

  • Two equivalent DMPA formulations are available: 150 mg intramuscularly every 13 weeks (Depo-Provera) or 104 mg subcutaneously every 13 weeks (DMPA-SC). 3, 5

  • Self-administered subcutaneous DMPA-SC is now recommended as an additional option that can improve contraceptive access and increase reproductive autonomy, though this is considered off-label use. 6, 3

Key Clinical Considerations Before Switching

  • Screen for new contraindications to progestin-only contraception, including history of stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, current breast cancer, and history of meningiomas. 3

  • Counsel about return to fertility differences: DMPA can delay return to fertility for 9-18 months after discontinuation, whereas COCs allow immediate return to fertility once stopped. 1, 5

  • Discuss expected menstrual changes: Most DMPA users experience irregular bleeding initially, with 57% developing amenorrhea by one year of use—a significant change from the predictable withdrawal bleeding with COCs. 7

  • Counsel about bone health: Recommend daily intake of 1300 mg calcium and 600 IU vitamin D, regular weight-bearing exercise, and smoking cessation, particularly for long-term use beyond 2 years. 3, 5

Follow-Up and Reinjection Schedule

  • No routine follow-up visit is required between injections, but patients should contact you to discuss side effects, method changes, or injection concerns. 6, 3, 5

  • Schedule repeat injections every 3 months (13 weeks), with a grace period allowing injections up to 2 weeks late (15 weeks from last injection) without requiring additional contraceptive protection. 6, 3, 5

  • If more than 15 weeks have elapsed since the last injection, verify the patient is not pregnant before administering the next dose and require backup contraception for 7 days. 3

Common Pitfalls to Avoid

  • Do not wait for a menstrual period before starting DMPA—this creates an unnecessary gap in contraceptive coverage and increases pregnancy risk. 1

  • Do not assume continuous contraceptive coverage without the 7-day backup period—even though there is overlap with the COC, the standard 7-day backup recommendation applies when initiating DMPA. 1

  • Do not forget to counsel about weight changes—patients should be informed that weight gain is a common side effect, and those with higher body weights may experience longer delays in return to fertility after discontinuation. 3, 4

  • Do not limit DMPA use to 2 years based solely on bone density concerns—the benefits of preventing unwanted pregnancy generally outweigh the risks of bone density loss. 5

References

Guideline

Switching from Depo-Provera to Seasonale

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Preventing gaps when switching contraceptives.

American family physician, 2011

Guideline

Approach to Administering Depo Shots

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Depo Provera Administration and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

3-month contraceptive injection approved.

FDA medical bulletin : important information for health professionals from the U.S. Food & Drug Administration, 1993

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.